Register for free
Recent Quotes
My Watchlist
Indicators
Business Insurance Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Intellia Therapeutics, Inc. - Common Stock (NQ:NTLA)

10.74 +0.01 (+0.09%)
Streaming Delayed Price Updated: 1:00 PM EDT, Jul 3, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Intellia Therapeutics, Inc. - Common Stock

< Previous 1 2
...
12 13 14 15 16 17 18 19 Next >
Intellia Therapeutics Posts Back To Back Positive Data From Gene Editing Therapies
Via Benzinga
Intellia Therapeutics Shares Are Gaining After Positive Data From Second CRISPR Candidate
Via Benzinga
Intellia Therapeutics Looks To Repeat Its Landmark Success In CRISPR Gene Editing
Intellia tested its CRISPR approach in cardiomyopathy and hereditary angioedema. 
Via Investor's Business Daily
Something Unusual Is Happening Right Now With Biotech Stocks Like Catalyst, Vertex, Neurocrine And BioMarin
The market is struggling, yet biotech stocks are acting like it's good times again. Here's why. 
Via Investor's Business Daily
Recap Of Thursday's Biotech Catalysts - End Of the Day Summary
Via Benzinga
Expert Ratings for Intellia Therapeutics
Intellia Therapeutics (NASDAQ:NTLA) has observed the following analyst ratings within the last quarter: 
Via Benzinga
Expert Ratings for Intellia Therapeutics
Within the last quarter, Intellia Therapeutics (NASDAQ:NTLA) has observed the following analyst ratings: 
Via Benzinga
Intellia Gets FDA Orphan Drug Status For Hereditary Angioedema Candidate
The U.S. Food and Drug Administration (FDA) has granted orphan drug designation for Intellia Therapeutics’ (NASDAQ: NTLA) lead asset NTLA-2002, for the treatment of hereditary angioedema (HAE).... 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For September 1, 2022
Upgrades 
Via Benzinga
Where Intellia Therapeutics Stands With Analysts
Over the past 3 months, 5 analysts have published their opinion on Intellia Therapeutics (NASDAQ:NTLA) stock. These analysts are typically employed by large Wall Street banks and tasked with... 
Via Benzinga
Recap: Intellia Therapeutics Q2 Earnings
  Intellia Therapeutics (NASDAQ:NTLA) reported its Q2 earnings results on Thursday, August 4, 2022 at 07:30 AM. Here's what investors need to know about the announcement. 
Via Benzinga
Intellia's Gene-Editing Candidate Shows Durability In ATTR Amyloidosis
Via Benzinga
BMO Initiates Coverage On This Gene Editing Spearhead
Via Benzinga
10 Health Care Stocks Whale Activity In Today's Session
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity... 
Via Benzinga
Why XPeng Shares Traded Lower By Around 11%; Here Are 77 Biggest Movers From Yesterday
Gainers 
Via Benzinga
Macy's, Palo Alto Networks And Other Big Gainers From Tuesday
U.S. stocks closed mostly lower with the Dow Jones dropping more than 150 points on Tuesday. Here is the list of some big stocks moving higher in the previous session. 
Via Benzinga
7 Monkeypox Vaccine Stocks to Buy Before They Shoot Higher
These monkeypox stocks could be among the best choices to buy in August. Each can make great investments as government responses ramp up. 
Via InvestorPlace
7 Stock Price Predictions That Are Actually Worth Listening To
Investors may take advantage of analyst stock price predictions beyond the recent share price to discover promising investments. 
Via InvestorPlace
Pfizer Is Reportedly In 'Advanced Talks' To Buy Global Blood Therapeutics For $5 Billion
Shares of Pfizer's rumored takeover target have rocketed for two days running. 
Via Investor's Business Daily
Alnylam's Hot Streak Cools As Expert Questions Uptake For Its Heart Drug
The company will compete with Pfizer, which already has an approved drug. 
Via Investor's Business Daily
Clorox, Crocs And Some Other Big Stocks Moving Lower On Thursday
  AMTD Digital Inc. (NYSE: HKD) dipped 43.6% to $620.00 on possible profit taking after the stock surged over the last few trading days. 
Via Benzinga
Intellia Gives Back Alnylam-Inspired Gains As Gene-Editing Safety Questioned
Intellia is backing off the higher dose of a gene-editing drug in cardiomyopathy patients. 
Via Investor's Business Daily
Biotech Daily: Amgen, Gilead Go Shopping, Nod For AstraZeneca's Lynparza In Early Stage Breast Cancer, Decision Day For Alzheimer's Associated Hallucinations Candidate
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
Why Are Gene Editing Stocks NTLA, ALNY, CRSP, BEAM Up Today?
Gene editing stocks are a bright spot on the market today after Alnylam announced the success of one of its RNAi therapies, Patisiran. 
Via InvestorPlace
7 Cathie Wood Stocks Trading at a Discount Right Now
These 7 Cathie Wood stocks are the best choices to buy in June. COIN, FATE, NTLA, MELI, TDOC, TSLA, and ZM can make excellent investments. 
Via InvestorPlace
10 Health Care Stocks With Whale Alerts In Today's Session
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity... 
Via Benzinga
The 3 Leaders of the Gene Editing Revolution
There's a wide field of gene editing stocks, but if you're looking for the best opportunities, there are a few likely winners to watch. 
Via InvestorPlace
7 Moonshot Investments Upending a $10 Trillion Industry
Gene editing is expensive at an estimated $5 billion per drug, but it could change the world in the very near future. 
Via InvestorPlace
Do You Have Biotech FOMO? It Might Be Time To Pay Attention To These Names
Biotech stocks continued going gangbusters Wednesday. Here's why, experts say. 
Via Investor's Business Daily
Do You Have Biotech FOMO? Why Cogent, Arvinas And Others Are Flying
Biotech stocks continued going gangbusters Wednesday. Here's why, experts say. 
Via Investor's Business Daily
< Previous 1 2
...
12 13 14 15 16 17 18 19 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.

Business Insurance is a singular, authoritative news and information source for executives focused upon risk management, risk transfer and risk financing.

Never miss important news. Subscribe to our newsletter.
Register for free

Information

Copyright 2024. BUSINESS INSURANCE HOLDINGS